VANCOUVER, BC , June 30, 2023 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB)(OTCQB: BVAXF) ("BioVaxys" or "Company") regrets to announce that Dasha Enenko has resigned as CFO of the Company to pursue other opportunities. BioVaxys CEO James Passin has been appointed as Acting CFO while the Board of Directors of the Company completes the search for a new CFO.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company based in Vacouver,Canada, is the exclusive US licensee and distributor of a portfolio of OTC female reproductive healthproducts currently marketed in the EU from Barcelona-based Procare Health Iberia, and is alsoentering clinical development for BVX-0918, a personalized immunotherapeutic vaccine using ourproprietary HapTenix© 'neoantigen' tumor cell construct platform for treating refractive late stageovarian cancer. The Company's OTC female reproductive system products include Papilocare®, a reepithelializing vaginal gel for the preventative and supportive treatment of lesions caused by HPV, andPapilocare® Immunocaps, a nutritional supplement that helps to normalize the vaginal microbiota andstrengthen natural immune defensesBioVaxys is also exploring vaccines for SARS-CoV-2, SARS-CoV1, and a pan-sarbecovirus vaccine based on its HapTenix©platform through academic collaborations.Novel Therapeutics. For Life.ON BEHALF OF THE BOARDSigned "James Passin"James Passin, CEO+1 646 452 7054Cautionary Statements Regarding Forward Looking InformationThis press release includes certain "forward-looking information" and "forward-looking statements"(collectively "forward-looking statements") within the meaning of applicable Canadian and UnitedStates securities legislation including the United States Private Securities Litigation Reform Act of1995. All statements, other than statements of historical fact, included herein, without limitation,statements relating the future operating or financial performance of the Company, are forwardlooking statements. Forward-looking statements are frequently, but not always, identified by wordssuch as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similarexpressions, or statements that events, conditions, or results "will", "may", "could", or "should" occuror be achieved. Forward-looking statements in this news release relate to, among other things, apotential listing of the Company on a US national stock exchange or completing a capital marketstransaction. There can be no assurance that such statementswill prove to be accurate, andactual results and future events could differ materially from those expressed or implied in suchforward-looking statements.These forward-looking statements reflect the beliefs, opinions and projections on the date thestatements are made and are based upon a number of assumptions and estimates. With regards toBioVaxys' business, there are a number of risks that could affect the development of itsbiotechnology products, including, without limitation, the need for additional capital to fund clinicaltrials, its lack of operating history, uncertainty about whether its products will complete the long,complex and expensive clinical trial and regulatory approval process for approval of new drugsnecessary for marketing approval, uncertainty about whether its autologous cell vaccineimmunotherapy can be developed to produce safe and effective products and, if so, whether itsvaccine products will be commercially accepted and profitable, the expenses, delays anduncertainties and complications typically encountered by development stage biopharmaceuticalbusinesses, financial and development obligations under license arrangements in order to protect itsrights to its products and technologies, obtaining and protecting new intellectual property rights andavoiding infringement to third parties and their dependence on manufacturing by third parties.TheCompany does not assume any obligation to update the forward-looking statements of beliefs,opinions, projections, or other factors, should they change, except as required by law.
Revolutionizing treatment delivery